• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients
【24h】

Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients

机译：替诺福韦联合或不联合干扰素对HIV-乙型肝炎-D型肝炎病毒感染患者丁型肝炎病毒复制的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The effect of tenofovir (TDF) alone or in combination with interferon on hepatitis D virus (HDV) replication is poorly characterized in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV. We analyzed triinfected patients undergoing treatment with either TDF alone (n=13) or including interferon (IFN) at some point during TDF therapy (TDF+IFN, n=4). Linear mixed-effect models were used to estimate the mean change from baseline of HDV-RNA and hepatitis surface antigen (HBsAg) levels during treatment. Patients were followed for a median 31.6 (25-75%-tile: 15.0-47.4) months. In the TDF+IFN group, three initiated IFN-based therapy after a median of 21.7 months (range=10.5-24.9) of lamivudine (LAM)+TDF, while the remaining patient had 46.8 months of prior LAM exposure. Significant decreases in HDV-RNA were observed in both groups [TDF alone:-0.380 log10 copies/ml per year (95% CI:-0.557,-0.202) vs. TDF+IFN:-1.325 log10 copies/ml per year (95% CI:-1.931,-0.720)], while the HDV-RNA decline overall was significantly faster in patients with TDF+IFN (p=0.002). Accordingly, two patients achieved HDV-RNA below the limit of quantification (LOQ: 1,000 copies/ml) and one near LOQ (1450 copies/ml), all concomitantly treated with interferon. There were no significant changes in HBsAg levels for either group [TDF alone:-0.008 log 10 IU/ml per month (95% CI:-0.019, 0.004), TDF+IFN:-0.011 log 10 IU/ml per month (95% CI:-0.037, 0.015)] and no significant difference in slope between treatment groups (p=0.8). Interferon therapy might be more effective after extended previous anti-HBV antiviral exposure among triinfected patients; however, the long-term implications of these findings remain unknown.
机译：在感染了人类免疫缺陷病毒（HIV），乙型肝炎病毒（HBV）和HDV的患者中，替诺福韦（TDF）单独或与干扰素联合使用对D型肝炎病毒（HDV）复制的影响不良。我们分析了三重感染的患者在TDF治疗期间的某个时间点接受单独TDF（n = 13）或包括干扰素（IFN）的治疗（TDF + IFN，n = 4）。线性混合效应模型用于估计治疗期间HDV-RNA与肝炎表面抗原（HBsAg）水平相对于基线的平均变化。对患者进行了中位31.6（25-75％瓷砖：15.0-47.4）个月的随访。在TDF + IFN组中，在拉米夫定（LAM）+ TDF的中位数为21.7个月（范围= 10.5-24.9）之后，三名患者开始了基于IFN的治疗，而其余患者在接受LAM之前为46.8个月。两组均观察到HDV-RNA显着降低[仅TDF：-0.380 log10拷贝/毫升每年（95％CI：-0.557，-0.202）与TDF + IFN：-1.325 log10拷贝/毫升每年（95 ％CI：-1.931，-0.720）]，而TDF + IFN患者的HDV-RNA总体下降明显更快（p = 0.002）。因此，两名患者的HDV-RNA低于定量限（LOQ：<1,000拷贝/ ml），一名接近LOQ（1450拷贝/ ml），所有患者均接受干扰素治疗。两组的HBsAg水平均无显着变化[仅TDF：-0.008 log 10 IU / ml每月（95％CI：-0.019，0.004），TDF + IFN：-0.011 log 10 IU / ml每月（95 ％CI：-0.037，0.015）]，治疗组之间的斜率没有显着差异（p = 0.8）。在三级感染患者中延长抗乙肝病毒抗病毒暴露水平后，干扰素治疗可能更有效。然而，这些发现的长期影响仍然未知。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号